Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA EBNA1/LMP2 Vaccine in Nasopharyngeal Cancer
NCT01094405Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Mar 2010
- Primary completion
- Aug 2020
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Modified Vaccinia Ankara EBNA1/LMP2 vaccine in nasopharyngeal carcinoma (NPC), sponsored by The Chinese University of Hong Kong. Started Mar 2010; status: completed.
02
Drugs
Modified Vaccinia Ankara EBNA1/LMP2 vaccine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT01094405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094405.